Patent · US Active

MEK1 mutation conferring resistance to RAF and MEK inhibitors

US9880169B2 · kind B2 · utility

0Cited by

54References

3Claims

0Family size

Assignee

DANA-FARBER CANCER INSTITUTE, INC. · US

Inventors

Levi A. Garraway · Newton, US
Caroline Emery · Brookline, US
Nikhil Wagle · Brookline, US

Key dates

Filing date	Jan 29, 2016
Grant date	Jan 30, 2018
Priority date	—
Expiry date	Jan 29, 2036

Classification

Technology area (CPC G)Physics
CPC primaryG01N2500/20
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Nucleic acids and proteins having a mutant MEK sequence, and methods concerning identification of patients having resistance to treatment with anti-cancer agents, specifically inhibitors of RAF or MEK are provided. Methods of treatment and for optimizing treatment for patients having a mutation in a MEK1 sequence are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.